Next Article in Journal
Mitochondrial H2O2 Is a Central Mediator of Diclofenac-Induced Hepatocellular Injury
Next Article in Special Issue
Pyridoxamine Limits Cardiac Dysfunction in a Rat Model of Doxorubicin-Induced Cardiotoxicity
Previous Article in Journal
Distinct or Overlapping Areas of Mitochondrial Thioredoxin 2 May Be Used for Its Covalent and Strong Non-Covalent Interactions with Protein Ligands
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Antioxidants
Volume 13
Issue 1
10.3390/antiox13010016
antioxidants-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Anti-Inflammation and Anti-Oxidation: The Key to Unlocking the Cardiovascular Potential of SGLT2 Inhibitors and GLP1 Receptor Agonists

by
Veronika A. Myasoedova
1,†,
Michele Bozzi
1,†,
Vincenza Valerio
1,
Donato Moschetta
1,
Ilaria Massaiu
1,
Valentina Rusconi
1,
Daniele Di Napoli
2,
Michele Ciccarelli
2,
Valentina Parisi
3,
Piergiuseppe Agostoni
1,
Stefano Genovese
1 and
Paolo Poggio
1,*
1
Centro Cardiologico Monzino IRCCS, 20138 Milan, Italy
2
Department of Medicine, Surgery and Dentistry, University of Salerno, 84084 Fisciano, Italy
3
Department of Translational Medical Sciences, Federico II University, 80138 Naples, Italy
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Antioxidants 2024, 13(1), 16; https://doi.org/10.3390/antiox13010016
Submission received: 6 November 2023 / Revised: 12 December 2023 / Accepted: 14 December 2023 / Published: 20 December 2023
(This article belongs to the Special Issue Crosstalk Between Oxidative Stress and Inflammation in Cardiovascular Diseases, Cancer and Neurodegeneration)
Browse Figures
Versions Notes

Abstract

Type 2 diabetes mellitus (T2DM) is a prevalent and complex metabolic disorder associated with various complications, including cardiovascular diseases. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP1-RA) have emerged as novel therapeutic agents for T2DM, primarily aiming to reduce blood glucose levels. However, recent investigations have unveiled their multifaceted effects, extending beyond their glucose-lowering effect. SGLT2i operate by inhibiting the SGLT2 receptor in the kidneys, facilitating the excretion of glucose through urine, leading to reduced blood glucose levels, while GLP1-RA mimic the action of the GLP1 hormone, stimulating glucose-dependent insulin secretion from pancreatic islets. Both SGLT2i and GLP1-RA have shown remarkable benefits in reducing major cardiovascular events in patients with and without T2DM. This comprehensive review explores the expanding horizons of SGLT2i and GLP1-RA in improving cardiovascular health. It delves into the latest research, highlighting the effects of these drugs on heart physiology and metabolism. By elucidating their diverse mechanisms of action and emerging evidence, this review aims to recapitulate the potential of SGLT2i and GLP1-RA as therapeutic options for cardiovascular health beyond their traditional role in managing T2DM.
Keywords: sodium-glucose cotransporter 2 inhibitors; glucagon-like peptide 1 receptor agonists; cardio-metabolism; oxidative stress; inflammation; fibrosis; epicardial adipose tissue sodium-glucose cotransporter 2 inhibitors; glucagon-like peptide 1 receptor agonists; cardio-metabolism; oxidative stress; inflammation; fibrosis; epicardial adipose tissue
Graphical Abstract

Share and Cite

MDPI and ACS Style

Myasoedova, V.A.; Bozzi, M.; Valerio, V.; Moschetta, D.; Massaiu, I.; Rusconi, V.; Di Napoli, D.; Ciccarelli, M.; Parisi, V.; Agostoni, P.; et al. Anti-Inflammation and Anti-Oxidation: The Key to Unlocking the Cardiovascular Potential of SGLT2 Inhibitors and GLP1 Receptor Agonists. Antioxidants 2024, 13, 16. https://doi.org/10.3390/antiox13010016

AMA Style

Myasoedova VA, Bozzi M, Valerio V, Moschetta D, Massaiu I, Rusconi V, Di Napoli D, Ciccarelli M, Parisi V, Agostoni P, et al. Anti-Inflammation and Anti-Oxidation: The Key to Unlocking the Cardiovascular Potential of SGLT2 Inhibitors and GLP1 Receptor Agonists. Antioxidants. 2024; 13(1):16. https://doi.org/10.3390/antiox13010016

Chicago/Turabian Style

Myasoedova, Veronika A., Michele Bozzi, Vincenza Valerio, Donato Moschetta, Ilaria Massaiu, Valentina Rusconi, Daniele Di Napoli, Michele Ciccarelli, Valentina Parisi, Piergiuseppe Agostoni, and et al. 2024. "Anti-Inflammation and Anti-Oxidation: The Key to Unlocking the Cardiovascular Potential of SGLT2 Inhibitors and GLP1 Receptor Agonists" Antioxidants 13, no. 1: 16. https://doi.org/10.3390/antiox13010016

APA Style

Myasoedova, V. A., Bozzi, M., Valerio, V., Moschetta, D., Massaiu, I., Rusconi, V., Di Napoli, D., Ciccarelli, M., Parisi, V., Agostoni, P., Genovese, S., & Poggio, P. (2024). Anti-Inflammation and Anti-Oxidation: The Key to Unlocking the Cardiovascular Potential of SGLT2 Inhibitors and GLP1 Receptor Agonists. Antioxidants, 13(1), 16. https://doi.org/10.3390/antiox13010016

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop